Solution-phase hydrogen/deuterium exchange (HDX) coupled to mass spectrometry (MS) is
a widespread tool for structural analysis across academia and the biopharmaceutical …

A number of different methods are commonly used to map the fine details of the interaction
between an antigen and an antibody. Undoubtedly the method that is now most commonly …

Hydrogen/deuterium exchange (HDX) detected by mass spectrometry (MS) is extraordinarily
useful in the study of many aspects of proteins, especially the analysis of protein …

Interaction of factor VIII (FVIII) with von Willebrand factor (VWF) is mediated by the VWF D′
D3 domains and thrombin-mediated release is essential for hemostasis after vascular injury …

Association with the D′ D3 domain of von Willebrand factor (VWF) stabilizes factor VIII
(FVIII) in the circulation and maintains it at a level sufficient to prevent spontaneous …

Inhibitor formation in hemophilia A is the most feared treatment-related complication of factor
VIII (fVIII) therapy. Most inhibitor patients with hemophilia A develop antibodies against the …

The development of inhibitory antibodies to therapeutic factor VIII is the major complication
of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti …

The immunogenicity of protein therapeutics is an important safety and efficacy concern
during drug development and regulation. Strategies to identify individuals and …

Antibody inhibitor development in hemophilia A represents the most significant complication
resulting from factor VIII (fVIII) replacement therapy. Recent studies have demonstrated that …

Background Deficiency in blood coagulation factor VIII (FVIII) results in life‐threating
bleeding (hemophilia A) treated by infusions of FVIII concentrates. To improve disease …